Drugs /

dacarbazine

Back to Drugs List

Overview

Generic Name(s):
dacarbazine
Trade Name(s):
Detimedac, Dtic-Dome, Asercit, Dacatic, Deticene, and Fauldetic
NCI Definition [1]:
A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04)

Clinical Trials

View Clinical Trials for dacarbazine

Dacarbazine has been investigated in 14 clinical trials, of which 14 are open and 0 are closed. Of the trials investigating dacarbazine, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (8 open), and 3 are phase 3 (3 open).

TNFRSF8 Expression, PML-RARA Fusion, and t(15;17)(q22;q12) are the most frequent biomarker inclusion criteria for dacarbazine clinical trials.

Classical hodgkin lymphoma, leiomyosarcoma, and alveolar soft part sarcoma are the most common diseases being investigated in dacarbazine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Dacarbazine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating dacarbazine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
DTIC-Dome, Asercit, Dacatic, Deticene, Detimedac, Fauldetic, dtic dome, dtie, 4-(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide, dtic, dtci, dacarbazine [chemical/ingredient], decarbazine, dic, dimethyl triazeno imidazol carboxamide, dacarbazinum, 1h-imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)-, imidazole carboxamide, dimethyl-triazeno-imidazole carboxamide, dakarbazin, dticdome, carboxamide, dimethyl imidazole, dic - dacarbazine, biocarbazine, 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide, 4342-03-4, imidazole carboxamide, dimethyl, 45388, dimethyl imidazole carboxamide, dacarbazina almirall, dacarbazine, icdt, imidazole carboxamide, 3188, 5-(3-3-dimethyl-1-triazenyl)-1h-imidazole-4-carboxamide, 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide, 5-(3,3-dimethyltriazeno)imidazole-4-carboxamide, 4-(dimethyltriazeno)imidazole-5-carboxamide, imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno)-, wr-139007, dacarbazin, dimethyltriazenoimidazole carboxamide, dacarbazine, 5-(dimethyltriazeno)imidazole-4-carboxamide, 5-(dimethyltriazeno)imidazole-4-carboxamide, dacarbazina, dimethyl triazeno imidazole carboxamide, 5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide, dacarbazine - dtic, imidazole carboxamide, dimethyl-triazeno-imidazole-carboximide, 1h-imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)-, imidazole carboxamide dimethyltriazeno, dtic - dacarbazine, icdmt, dimethyl (triazeno) imidazolecarboxamide, dacarbazine (product), dacarbazine (substance), dimethyl-triazeno-imidazole carboxamide
Drug Categories [2]:
Alkylating agents
NCIT ID [1]:
C411
SNOMED ID [1]:
F-61BAE

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.